Our kidneys play a vital role in maintaining fluid balance and filtering waste from our blood. However, they are often silently damaged over time due to conditions like diabetes, high blood pressure etc. Traditional markers like serum creatinine and glomerular filtration rate (GFR) usually detect advanced kidney damage that has already happened. But now, new renal biomarkers are enabling early detection of kidney injury even before loss of kidney function occurs. These biomarkers hold promise for improving diagnosis, monitoring treatment response and outcomes in kidney diseases.
What are Renal Biomarkers?
Renal biomarkers are substances found in urine or blood that indicate the presence of kidney damage. They are usually byproducts of normal kidney structures like tubules, podocytes or glomeruli that leak into urine or blood when those structures are injured. Some commonly used renal biomarkers include neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), liver-type fatty acid binding protein (L-FABP), interleukin-18 (IL-18) etc. These biomarkers have higher sensitivity and ability to detect even subclinical kidney injury earlier than traditional tests.
Diagnosing Acute Kidney Injury
One of the major applications of renal biomarkers is in early diagnosis of acute kidney injury (AKI). Conditions like sepsis, major surgeries, kidney transplantation etc. can suddenly damage the kidneys and cause AKI. Traditional tests usually fail to detect AKI in its early, reversible stages. But renal biomarkers like NGAL, KIM-1 and IL-18 measured in urine have shown to predict and detect AKI up to 24 hours earlier than rise in serum creatinine. This early diagnosis is crucial as it provides a wider therapeutic window to prevent progression of AKI. Several studies demonstrate that combined use of multiple urinary renal biomarkers improves diagnosis of AKI compared to any single biomarker alone.
Monitoring Chronic Kidney Disease
Renal Biomarkers also assist in managing chronic kidney disease (CKD), a major public health problem. CKD is usually a slow, progressive loss of kidney functions over years. Traditional eGFR and urinary albumin testing used for CKD staging often misses early disease activity and progression. Emerging biomarkers like neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule 1 (KIM-1) etc. can detect subclinical tubular injury in early CKD stages. Serial monitoring of these biomarkers may help recognize accelerating CKD much before decline in eGFR occurs. It also provides objective assessment of treatment response in CKD. Several studies show that reduction in urinary biomarker levels after initiation of renin-angiotensin system inhibitors correlates with slower CKD progression.
Predicting Transplant Outcomes
Kidney transplantation is the best treatment for end stage kidney disease. However, acute cellular rejection and long term allograft loss continue to be major challenges. Novel renal biomarkers can help identify recipients at high risk. For example, elevated urinary biomarkers in early post-transplant period predict higher risk of acute cellular rejection. Similarly, persistently high urinary biomarker levels months after transplant correlate with development of chronic allograft injury and graft loss in long term. Using a panel of urinary biomarkers may help clinicians detect subclinical rejection early to guide therapeutic decisions. It could also predict long term outcomes to counsel preemptively. Thus, renal biomarkers hold promise for improving monitoring strategies in kidney transplantation.
Personalized Medicine and New Therapies
With growing understanding about mechanisms of kidney injury, renal biomarkers are also enabling development of targeted therapies. For example, NGAL inhibits apoptosis of kidney cells and stimulates regeneration. Early elevation of urinary NGAL after AKI identifies patients who may benefit most from recombinant NGAL treatment being researched. Similarly, KIM-1 binds with oxalate to protect against calcium oxalate crystal formation in kidneys. Drugs modulating the KIM-1 pathway show promise for preventing recurrent kidney stones. In future, analyzing an individual patient’s urinary biomarker profile may allow selection of most appropriate therapies based on specific pathways of their kidney disease. Such personalized medicine approach tailored to disease mechanisms holds potential for improving outcomes across broad spectrum of kidney diseases.
Get more insights on Renal Biomarkers
Also read related article on Molecular Imaging Market
